busulfan has been researched along with Neutropenia in 23 studies
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since 1997, 32 newly diagnosed multiple myeloma patients responsive to DAV chemotherapy were autografted with idarubicin-intensified busulphan-melphalan (ida-bu-mel)." | 7.73 | High-dose idarubicin, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma responsive to DAV chemotherapy: comparison with a historical control. ( Baldacci, E; Capria, S; de Propris, MS; Meloni, G; Petrucci, MT; Pulsoni, A; Ribersani, M, 2006) |
| " We developed an at-home ASCT program in which prophylactic ceftriaxone and treatment of febrile neutropenia with piperacillin and tazobactam was introduced to minimize the readmission rate." | 5.12 | Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. ( Carreras, E; Fernández-Avilés, F; Gallego, C; García, L; Gaya, A; González, M; Granell, M; Hernando, A; Martínez, C; Montserrat, E; Ramiro, L; Rovira, M; Segura, S; Urbano-Ispizua, A; Valverde, M, 2006) |
| "Autologous stem cell transplantation after high-dose melphalan for the treatment with multiple myeloma has resulted in prolonged progression-free survival and overall survival in patients under 65 years." | 5.09 | The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. ( Bhagwati, N; Horton, C; Kulkarni, S; Mainwaring, P; Mehta, J; Pandha, H; Powles, R; Singhal, S; Sirohi, B; Treleaven, J, 2000) |
| "Since 1997, 32 newly diagnosed multiple myeloma patients responsive to DAV chemotherapy were autografted with idarubicin-intensified busulphan-melphalan (ida-bu-mel)." | 3.73 | High-dose idarubicin, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma responsive to DAV chemotherapy: comparison with a historical control. ( Baldacci, E; Capria, S; de Propris, MS; Meloni, G; Petrucci, MT; Pulsoni, A; Ribersani, M, 2006) |
| " Fifty-eight patients (median age, 67 years; range, 54 to 76) received radioimmunotherapy followed by fludarabine 150 mg/m(2) and busulfan 8 mg/kg combined with either 75 mg (n = 26) or 50 mg (n = 32) alemtuzumab." | 2.80 | Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion. ( Bornhäuser, M; Ehninger, G; Kotzerke, J; Schetelig, J; Schneider, S; Strumpf, A; Wunderlich, G, 2015) |
| "For patients with relapsed or refractory multiple myeloma (MM) treated with a prior high-dose therapy (HDT) followed by autologous peripheral blood stem cell transplantation (PBSCT), the reapplication of HDT is a widely used salvage strategy." | 2.76 | Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. ( Balleisen, S; Bruns, I; Fenk, R; Haas, R; Kobbe, G; Kondakci, M; Liese, V; Neubauer, F; Saure, C; Schröder, T, 2011) |
| "We treated 51 patients with various hematological malignancies involving the bone marrow with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) followed by reinfusion of autologous peripheral blood stem cells." | 2.68 | Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery. ( Agaliotis, DP; Ballester, OF; Elfenbein, GJ; Fields, KK; Goldstein, SC; Hiemenz, JW; Janssen, WE; Perkins, JB; Zorksy, PE, 1996) |
| " G-CSF was given at variable dosage based on neutrophil count." | 2.66 | Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. ( Dodds, A; Fox, RM; Green, MD; Layton, JE; Lusk, J; Maher, D; Morstyn, G; Sheridan, WP; Souza, L; Wolf, M, 1989) |
| "Stem cell transplants are often used to treat severe aplastic anemia or, alternatively, may be part of the treatment for an underlying malignant disease or a genetic disease." | 2.42 | Hematopoietic stem cells. ( Trigg, ME, 2004) |
| " We aimed this retrospective study for comparison of weight- and age-based dosing in terms of clinical outcomes such as time to engraftment, early complications, EFS, OS, and toxicity profiles in children receiving iv Bu." | 1.42 | Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation. ( Avci, Z; Azik, F; Gürlek Gökçebay, D; Isik, P; Kara, A; Ozbek, N; Tavil, B; Tunc, B, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.04) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 12 (52.17) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gürlek Gökçebay, D | 1 |
| Azik, F | 1 |
| Ozbek, N | 1 |
| Isik, P | 1 |
| Avci, Z | 1 |
| Tavil, B | 1 |
| Kara, A | 1 |
| Tunc, B | 1 |
| Schneider, S | 1 |
| Strumpf, A | 1 |
| Schetelig, J | 1 |
| Wunderlich, G | 1 |
| Ehninger, G | 1 |
| Kotzerke, J | 1 |
| Bornhäuser, M | 1 |
| Kang, EM | 1 |
| Choi, U | 1 |
| Theobald, N | 1 |
| Linton, G | 1 |
| Long Priel, DA | 1 |
| Kuhns, D | 1 |
| Malech, HL | 1 |
| Fenk, R | 1 |
| Liese, V | 1 |
| Neubauer, F | 1 |
| Bruns, I | 1 |
| Kondakci, M | 1 |
| Balleisen, S | 1 |
| Saure, C | 1 |
| Schröder, T | 1 |
| Haas, R | 1 |
| Kobbe, G | 1 |
| Facchini, L | 1 |
| Martino, R | 1 |
| Ferrari, A | 1 |
| Piñana, JL | 1 |
| Valcárcel, D | 1 |
| Barba, P | 1 |
| Granell, M | 2 |
| Delgado, J | 1 |
| Briones, J | 1 |
| Sureda, A | 1 |
| Brunet, S | 1 |
| Sierra, J | 1 |
| Kállay, K | 1 |
| Liptai, Z | 1 |
| Benyó, G | 1 |
| Kassa, C | 1 |
| Goda, V | 1 |
| Sinkó, J | 1 |
| Tóth, A | 1 |
| Kriván, G | 1 |
| Hori, A | 1 |
| Kami, M | 1 |
| Kim, SW | 1 |
| Chizuka, A | 1 |
| Kojima, R | 1 |
| Imataki, O | 1 |
| Sakiyama, M | 1 |
| Hamaki, T | 1 |
| Onishi, Y | 1 |
| Usubuchi, N | 1 |
| Kishi, Y | 1 |
| Murashige, N | 1 |
| Tajima, K | 1 |
| Miyakoshi, S | 1 |
| Heike, Y | 1 |
| Masuo, S | 1 |
| Taniguchi, S | 1 |
| Takaue, Y | 1 |
| Mino, E | 1 |
| Kobayashi, R | 1 |
| Yoshida, M | 1 |
| Suzuki, Y | 1 |
| Yamada, M | 1 |
| Kobayashi, K | 1 |
| Trigg, ME | 1 |
| Valteau-Couanet, D | 2 |
| Faucher, C | 1 |
| Aupérin, A | 1 |
| Michon, J | 1 |
| Milpied, N | 1 |
| Boiron, JM | 1 |
| Bourhis, JH | 1 |
| Gisselbrecht, C | 1 |
| Vernant, JP | 1 |
| Pinna, A | 1 |
| Bendahmane, B | 1 |
| Delabarre, F | 1 |
| Benhamou, E | 1 |
| Capria, S | 1 |
| Petrucci, MT | 1 |
| Pulsoni, A | 1 |
| Ribersani, M | 1 |
| Baldacci, E | 1 |
| de Propris, MS | 1 |
| Meloni, G | 1 |
| Kiefer, T | 1 |
| Krüger, WH | 1 |
| Schüler, F | 1 |
| Lotze, C | 1 |
| Hirt, C | 1 |
| Dölken, G | 1 |
| Cojean, N | 1 |
| Blondet, C | 1 |
| Marcellin, L | 1 |
| Entz-Werlé, N | 1 |
| Babin, A | 1 |
| Constantinesco, A | 1 |
| Lutz, P | 1 |
| Chunduri, S | 1 |
| Dobogai, LC | 1 |
| Peace, D | 1 |
| Saunthararajah, Y | 1 |
| Chen, HY | 1 |
| Mahmud, N | 1 |
| Quigley, J | 1 |
| Hoffman, R | 1 |
| Jessop, E | 1 |
| Beri, R | 1 |
| Rondelli, D | 1 |
| Fernández-Avilés, F | 1 |
| Carreras, E | 1 |
| Urbano-Ispizua, A | 1 |
| Rovira, M | 1 |
| Martínez, C | 1 |
| Gaya, A | 1 |
| Ramiro, L | 1 |
| Gallego, C | 1 |
| Hernando, A | 1 |
| Segura, S | 1 |
| García, L | 1 |
| González, M | 1 |
| Valverde, M | 1 |
| Montserrat, E | 1 |
| Ridola, V | 1 |
| Grill, J | 1 |
| Doz, F | 1 |
| Gentet, JC | 1 |
| Frappaz, D | 1 |
| Raquin, MA | 1 |
| Habrand, JL | 1 |
| Sainte-Rose, C | 1 |
| Kalifa, C | 1 |
| Tsuji, Y | 1 |
| Imai, K | 1 |
| Morinishi, Y | 1 |
| Kogawa, K | 1 |
| Morino, M | 1 |
| Nonoyama, S | 1 |
| Srivastava, A | 1 |
| Bradstock, KF | 1 |
| Szer, J | 1 |
| de Bortoli, L | 1 |
| Gottlieb, DJ | 1 |
| Ballester, OF | 1 |
| Agaliotis, DP | 1 |
| Hiemenz, JW | 1 |
| Janssen, WE | 1 |
| Fields, KK | 1 |
| Zorksy, PE | 1 |
| Goldstein, SC | 1 |
| Perkins, JB | 1 |
| Elfenbein, GJ | 1 |
| Sirohi, B | 1 |
| Powles, R | 1 |
| Treleaven, J | 1 |
| Mainwaring, P | 1 |
| Kulkarni, S | 1 |
| Pandha, H | 1 |
| Bhagwati, N | 1 |
| Horton, C | 1 |
| Singhal, S | 1 |
| Mehta, J | 1 |
| Andersen, BR | 1 |
| Debelak-Fehir, KM | 1 |
| Epstein, RB | 1 |
| Sheridan, WP | 1 |
| Morstyn, G | 1 |
| Wolf, M | 1 |
| Dodds, A | 1 |
| Lusk, J | 1 |
| Maher, D | 1 |
| Layton, JE | 1 |
| Green, MD | 1 |
| Souza, L | 1 |
| Fox, RM | 1 |
| Udupa, KB | 1 |
| Reissmann, KR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Autologous Transplantation of Genetically Modified Cells for the Treatment of X-Linked Chronic Granulomatous Disease[NCT00394316] | Early Phase 1 | 3 participants (Actual) | Interventional | 2006-10-30 | Terminated | ||
| Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency[NCT01306019] | Phase 1/Phase 2 | 19 participants (Actual) | Interventional | 2012-09-25 | Suspended (stopped due to Clones representing 10% or more of the subject patients myeloid lineage have been detected, no evidence of malignancy found.) | ||
| A Multicentric, Exploratory, Non-randomised, Non-controlled, Prospective, Open-label Phase II Study Evaluating Safety and Efficacy of IBU, G-CSF and Plerixafor as Stem Cell Mobilization Regimen in Patients Affected by X-CGD[NCT03055247] | Phase 2 | 3 participants (Anticipated) | Interventional | 2015-11-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for busulfan and Neutropenia
| Article | Year |
|---|---|
Hematopoietic stem cells.
Topics: Anemia, Aplastic; Antineoplastic Agents; Busulfan; Child; Fetal Blood; Hematopoietic Stem Cell Trans | 2004 |
10 trials available for busulfan and Neutropenia
| Article | Year |
|---|---|
Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
Topics: Aged; Alemtuzumab; Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, | 2015 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Busulfan; Co | 2011 |
Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning.
Topics: Adult; Bacterial Infections; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transp | 2012 |
Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial.
Topics: Adolescent; Adult; Aged; Blood Transfusion; Busulfan; Child; Child, Preschool; Cost-Benefit Analysis | 2005 |
Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Hematologic | 2006 |
Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Busul | 2006 |
Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Combined Modalit | 1996 |
The role of autologous transplantation in patients with multiple myeloma aged 65 years and over.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Chem | 2000 |
Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation.
Topics: Agranulocytosis; Bone Marrow Examination; Bone Marrow Transplantation; Busulfan; Clinical Trials as | 1989 |
12 other studies available for busulfan and Neutropenia
| Article | Year |
|---|---|
Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation.
Topics: Adolescent; Age Factors; Body Weight; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; F | 2015 |
Successful unrelated umbilical cord blood transplantation in Lesch-Nyhan syndrome.
Topics: Busulfan; Child Development; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamid | 2012 |
Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Child; Child, Preschool; C | 2004 |
Umbilical cord blood stem cell transplantation from unrelated HLA-matched donor in an infant with severe congenital neutropenia.
Topics: Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; DNA Fingerprinting; | 2004 |
High-dose idarubicin, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma responsive to DAV chemotherapy: comparison with a historical control.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2006 |
The modification of high-dose therapy shortens the duration of neutropaenia by delay of leucocyte nadir.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Infec | 2006 |
Successful stem cell transplantation in an infant with severe congenital neutropenia complicated by pretransplant inflammatory pseudotumor of the liver.
Topics: Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc | 2006 |
High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Busulfan; Cerebellar Neoplasms; Child | 2007 |
Successful unrelated cord blood transplantation for a patient with CD40 ligand deficiency.
Topics: Agammaglobulinemia; Busulfan; CD40 Antigens; Cord Blood Stem Cell Transplantation; Cyclophosphamide; | 2007 |
Busulphan and melphalan prior to autologous bone marrow transplantation.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone | 1993 |
Effect of bone marrow suppression on granulocyte opsonin levels.
Topics: Agranulocytosis; Animals; Busulfan; Complement C3; Complement System Proteins; Cyclophosphamide; Dog | 1976 |
Acceleration of granulopoietic recovery by androgenic steroids in mice made neutropenic by cytotoxic drugs.
Topics: Agranulocytosis; Androgens; Animals; Bone Marrow; Busulfan; Carmustine; Cell Division; Clone Cells; | 1974 |